Roche has made another MAGE-A4 program disappear, withdrawing a phase 1 trial of a T-cell bispecific prospect before a single ...

The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing ...

Supernus Pharmaceuticals has linked its mTORC1 activator to rapid improvements in adults with major depressive disorder in a ...

It’s been a whirlwind year for Joerg Moeller, M.D. After being appointed CEO of BenevolentAI in January, Moeller is now out ...

Earlier this year, Intuitive Surgical warned that supplies may be tight in the months ahead as it continues to roll out the ...

Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season.

Sage Therapeutics’ latest attempt to shrink its pipeline and workforce will see a third of the biotech’s employees heading ...

Taiwan’s REGiMMUNE and Europe-based Kiji Therapeutics are merging to create a globally minded regulatory T-cell biotech that ...

Johnson & Johnson is jettisoning several programs, with three of the culls taking place in the neuroscience field. | Johnson ...

London-based GSK is crossing the pond to form a new lung disease research collaboration with Boston scientists. | ...

Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. | Novartis is paying ...

After spying blockbuster potential in Longboard Pharmaceuticals’ epilepsy med, brain disease-focused pharma Lundbeck is ...